Effects of rosuvastatin and ezetimibe on bone turnover markers in type 2 diabetes patients with hypercholesterolemia
Not Applicable
Completed
- Conditions
- hypercholesterolemia with type 2 diabetes
- Registration Number
- JPRN-UMIN000001993
- Lead Sponsor
- Department of Internal Medicine 1, Shimane University School of Medicine
- Brief Summary
Serum osteocalcin levels in the rosuvastatin group were significantly increased, while any bone marker in the ezetimibe group was not changed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Nobody had hepatic or renal dysfunction or nutritional derangements. All patients were free of drugs known to influence bone and calcium metabolism, such as vitamin D, bisphosphonate, or estrogen, up until the time of the study. Nobody had treatments with any cholesterol lowering agent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method